LKYSF - Psychedelics Transition from Experimental Treatment to Major Pharmaceutical Industry

Psychedelic medicine is emerging as a breakthrough for mental health. After decades of research, drugs like psilocybin and ketamine are finally ready to move from the lab into the pharmacy and the therapist’s office. Several psychedelic treatments have already received approval from the US Food and Drug Administration (FDA), including Johnson & Johnson’s (NYSE:JNJ) ketamine-life depression drug, and more are likely to follow suit in the years to come. Now that the FDA has come to realize the potential benefits of psychedelic medicines, pioneering biotechnology companies like Compass Pathways (NASDAQ:CMPS), Numinus Wellness Inc. (TSXV:NUMI) (OTC:LKYSF), Mind Medicine (MindMed) ...